Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

GA001 Injection in Retinitis Pigmentosa

13. november 2026 opdateret af: GenAns Biotechnology Co., Ltd

A Clinical Study to Evaluate the Safety and Efficacy of GA001 Injection in Patients With Retinitis Pigmentosa

This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Retinitis pigmentosa (RP) is an inherited retinal disease that causes gradual vision loss and can lead to blindness, with no approved curative treatment currently available.

This Phase II study is designed to evaluate the safety, tolerability, and efficacy of a single unilateral intravitreal injection of GA001 Injection at the target dose compared with sham injection in patients with retinitis pigmentosa. The study employs a sham-controlled design and will assess safety and efficacy outcomes as well as multiple functional and structural measures of visual performance over long-term follow-up.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

12

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Xiaodong Sun Principal Investigator, PhD
  • Telefonnummer: 86 17853138155
  • E-mail: xdsun@sjtu.edu.cn

Studiesteder

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200080
        • Shanghai General Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female participants aged 18 to 70 years.
  2. Clinical diagnosis of advanced retinitis pigmentosa (RP).
  3. Best corrected visual acuity at or below the protocol-defined threshold in the study eye.
  4. Ability to understand and sign informed consent (and assent, when applicable).
  5. Laboratory test results are within the protocol-defined threshold range.

Exclusion Criteria:

  1. Presence of other ocular conditions that could interfere with study assessments.
  2. History of significant ocular surgery in the study eye within a protocol-defined period.
  3. Active ocular infection or inflammation.
  4. Clinically significant systemic disease that could increase study risk or interfere with assessments.
  5. Positive screening for clinically significant infectious diseases, as defined in the protocol.
  6. Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation.
  7. Pregnant or breastfeeding individuals.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: GA001

Single unilateral IVT injection of GA001 Injection in the study eye

Sham-komparator: Sham Injection

Sham IVT procedure in the study eye

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate the efficacy of GA001 Injection in patients with retinitis pigmentosa
Tidsramme: Baseline to Week 52

BCVA-Change from Baseline in LogMAR Best Corrected Visual Acuity (BCVA) BCVA assessed by ETDRS charts at each post-treatment visit compared with the sham group.baseline→W52,Unit: LogMAR

MLMT-Change from Baseline in Multi-Luminance Mobility Test (MLMT) Performance MLMT 7 levels; baseline→W52 ambient Lux to finish course, vs. sham. Unit: Lux

Light Sensitivity-Change from Baseline in Light Sensitivity (Minimum Identifiable Brightness) Min brightness (Lux), study eye; baseline→W52, vs. sham. Unit: Lux

FST Threshold-Change from Baseline in Full-Field Stimulus Test (FST) Threshold Full-field stimulus test; baseline→W52, vs. sham. Unit: log cd·s/m²

Central Visual Field-Change from Baseline in Central Visual Field Static perimetry; baseline→W52, vs. sham. Unit: dB (mean deviation)

MRDQ-Change from Baseline in Michigan Retinal Degeneration Questionnaire (MRDQ) Total Score MRDQ total score; baseline→W52, vs. sham. Unit: total score (points)

Baseline to Week 52

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Treatment-Emergent Adverse Events and serious adverse events
Tidsramme: Baseline to Week 52

Incidence of severity of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following a single intravitreal injection of GA001

Baseline to Week 52
Evaluation of the Immunogenicity of GA001 Injection after a Single Intravitreal Administration in Patients with Retinitis Pigmentosa
Tidsramme: Baseline to Week 52

Immunogenicity of GA001 Injection will be evaluated following a single intravitreal injection in patients with retinitis pigmentosa, by AAV neutralizing antibody titers in peripheral blood (cell-based neutralizing assay) and by analysis of GA001-specific T-cell immune responses.

Baseline to Week 52
Maximum Concentration (Cmax) of GA001 Vector DNA
Tidsramme: Baseline to Week 52

Cmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

Baseline to Week 52
Area Under the Concentration-Time Curve (AUC) of GA001 Vector DNA
Tidsramme: Baseline to Week 52

AUC of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

Baseline to Week 52
Time to Maximum Concentration (Tmax) of GA001 Vector DNA
Tidsramme: Baseline to Week 52

Tmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

Baseline to Week 52
Biodistribution of GA001 Vector DNA
Tidsramme: Baseline to Week 52

Biodistribution of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

Baseline to Week 52
Shedding of GA001 Vector DNA
Tidsramme: Baseline to Week 52

Shedding of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa.

Baseline to Week 52

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. april 2027

Primær færdiggørelse (Anslået)

25. november 2029

Studieafslutning (Anslået)

25. november 2031

Datoer for studieregistrering

Først indsendt

2. november 2026

Først indsendt, der opfyldte QC-kriterier

13. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • GA001-2025

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .